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ABSTRACT Conversion of the cellular isoform of prion
protein (PrPc) into the scrapie isoform (PrPSc) involves an
increase in the /3-sheet content, diminished solubility, and
resistance to proteolytic digestion. Transgenetic studies argue
that PrPc and PrPSc form a complex during PrPScformation;
thus, synthetic PrP peptides, which mimic the conformational
pluralism of PrP, were mixed with PrPc to determine whether
its properties were altered. Peptides encompassing two a-he-
lical domains of PrP when mixed with PrPc produced a
complex that displayed many properties of PrPSc. The PrPc-
peptide complex formed fibrous aggregates and up to 65% of
complexed PrPc sedimented at 100,000 x g for 1 h, whereas
PrPc alone did not. These complexes were resistant to pro
teolytic digestion and displayed a high /3-sheet content. Un
expectedly, the peptide in a /3-sheet conformation did not form
the complex, whereas the random coil did. Addition of 2%
Sarkosyl disrupted the complex and rendered PrPc sensitive
to protease digestion. While the pathogenic AllTV mutation
increased the efficacy of complex formation, anti-PrP mono
clonal antibody prevented interaction between PrPc and pep
tides. Our findings in concert with transgenetic investigations
argue that PrPc interacts with PrPSc through a domain that
contains the first two putative a-helices. Whether PrPc-pep-
tide complexes possess prion infectivity as determined by
bioassays remains to be established.
Although many lines of evidence have converged to argue
persuasively that prions are composed of the scrapie isoform
of prion protein (PrPSc) (1), identifying conditions for the in
vitro conversion of the cellular isoform (PrPc) into PrPSc
wherein scrapie infectivity is generated de novo remains to be
accomplished. Formation of PrPSc is a posttranslational pro
cess (2) in whichPrPc forms a complexwith PrPSc and is then
transformed into a second molecule of PrPSc (3). While
attempts to detect a covalent change that distinguishes PrPc
from PrPSc were unsuccessful (4), spectroscopic studies dem
onstrated that PrPc contains —40% cv-helix and is devoid of
0-sheet (5). In contrast, PrPSc has a high 0-sheet content,
which correlates with scrapie infectivity (6-9).
Once studies of mice expressing Syrian hamster (SHa) PrP
transgenes indicated that PrPc and PrPSc form a complex
during the formation of nascent PrPSc (3), we attempted to
demonstrate PrPSc production through formation of such
complexes by mixing purified fractions containing equimolar
amounts of the two isoforms (10). Unable to demonstrate
conversion of PrPc into PrPSc in these mixtures, we pursued the
interactions of synthetic PrP peptides that correspond to
regions of putative secondary structure and display confor
mational pluralism (11,12). In contrast to our earlier findings,
other investigators were able to demonstrate an interaction
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between PrPSc and PrPc by mixing a 50-fold excess of PrPSc
with labeled PrPc (13).
In the current study, PrP peptides encompassing the first two
putative a-helical regions and mimicking many structural
features of the two PrP isoforms(14,15) were mixedwith PrPc,
which became resistant to proteolytic digestion and sedi
mented at 100,000 Xg for 1 h. Mixtures of PrPc and peptides
formed fibrous aggregates and displayed a high /3-sheet con
tent. Addition of 2% Sarkosyl disrupted the PrPc-peptide
complex and rendered PrPc sensitive to protease digestion;
anti-PrP monoclonal antibody (mAb) prevented complex for
mation. Unexpectedly, the peptide in a 0-sheet conformation
did not bind PrPc, whereas the random coil did. When the
pathogenic A117V mutation causing both the telencephalic
and ataxic forms of Gerstmann-Straussler-Scheinker disease
(16-18) was substituted in the peptide, =65% of the radiola
beled PrPc formed sedimentable complexes. Our findings in
concert with transgenetic investigations argue that PrPc inter
acts with PrPSc through a domain that contains the first two
putative a-helices.
MATERIALS AND METHODS
SHaPrP was subcloned into the glutamine synthetase expres
sion vector pEE 12 (Cell/Tech, Alameda, CA). Chinese
hamster ovary (CHO) Kl cells (American Type Culture Col
lection) were seeded at 106 cells per 10-cm dish in GMEM-S
medium containing 10% dialyzed fetal calf serum (GIBCO/
BRL) (19). Cells were transfected with 10 /ig of pEE 12-
SHaPrP vector per dish by the CaP04 method (20). After
growing cells in 25 /u,M methionine sulfoximine (MSX) (Sig
ma) for 2 weeks, 60 clones were selected and grown in 100,200,
or 400 jjM MSX. The clones were analyzed by Western blotting
to identify the highest expressors (21). From clone 30C1,
phosphatidylinositol-specific phospholipase C digestion re
leased -90 ng of SHaPrPc from 106 cells (22).
The CHO cells expressing SHaPrPc were metabolically
radiolabeled with [35S]methionine (100 jxCi/ml; 1 Ci = 37
GBq; NEN) (2) and immunoaffinity purified (23) from cell
lysates by using the anti-PrP 3F4 mAb (24), which recognizes
SHaPrP residues 109-112 (25). SHaPrPc was eluted from
mAb/protein A-Sepharose with 3 M guanidine hydrochloride
(Gdn-HCl) and centrifuged at 16,000 Xg for 2 min at 4°C, and
the supernatant was diluted 1:10 in TN buffer composed of 130
mM NaCl and 10 mM Tris-HCl (pH 7.4); in some cases, PrPc
was precipitated with 4 vol of methanol to separate it from the
Gdn-HCl and residual detergent. 35S-labeled PrPc (35S-PrPc)
concentrations were determined by comparison with signals
from Western blots with known quantities of PrPc from SHa
brain and by measurements in a scintillation spectrometer.
Abbreviations: PrP, prion protein; PrPc, cellular isoformof PrP; PrPSc,
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SHa (Lak:LVG) obtained from Charles River Breeding
Laboratories were inoculated with Sc237 prions (26) and
sacrificed when they showed signs of central nervous system
dysfunction. SHaPrPSc was purified from the brains of these ill
animals (27). Similarly, mouse (Mo) PrPSc was purified from
the brains of ill mice inoculated with RML prions (28).
SHaPrPc was purified from the brains of uninoculated adult
SHa (5) and radioiodinated with 125I (1 mCi per 100 /u,g of
PrPc; Amersham) using Iodo-Beads (Pierce) (29).
PrP peptides were synthesized and purified as described;
conformations were established by Fourier transform infrared
spectroscopyand CD (12,14). Proteinase K (GIBCO/BRL) was
used at a concentration of 50 ju-g/ml and incubated for 1 h at 37°C.
Although PrPsc was digested in 3 M Gdn-HCl, in some cases the
activity of proteinase K was reduced =90%, as measured by a
colorimetric assay with carbobenzoxyvalylglycylarginine p-
nitroanilide (Boehringer Mannheim). Digestions with proteinase
K were terminated by addition of 1 mM (4-amidinophenyl)
methanesulfonyl fluoride (Boehringer Mannheim). SDS/PAGE
was performed according to Laemmli (30) and autoradiograms
were obtained. Immunoblots were performed using the ECL
system (Amersham) with anti-PrP 3F4 mAb. Using a JEOL
100CX electron microscope, samples were viewed at 80 keV after
negative staining.
Fifty nanograms of 35S-SHaPrPc at a concentration =10
ju,g/mlwas incubated in Eppendorf microcentrifuge tubes with
TN buffer for up to 48 h at 37°C. PrP peptides were mixed with
immunopurified, radiolabeled PrPc in 0.3 M Gdn-HCl at molar
ratios ranging from 50:1 to 5000:1. Anti-PrP 3F4 and 13A5
mAbs (31) were added to SHaPrPc in molar ratios of 500:1 or
1000:1. SHa- or MoPrPSc was incubated with SHaPrPc in mo
lar ratios ranging from 1:1 to 50:1. The PrPSc (=1 mg/ml) was
pretreated with Gdn-HCl at concentrations ranging from 0 to
6 M for 16 h at 37°C. Upon termination of the incubation, an
equal volume of TN buffer was added to all samples and
analyses were performed immediately.
RESULTS
PrP Peptides Promote Formation of Protease-Resistant
PrP. Having found that small PrP peptides can interact and
induce conformational changes (12) and that a 56-residue
peptide denoted SHa 90-145, which corresponds to the N
terminus of PrP 27-30, displayed multiple conformations (14),
we asked if synthetic peptides mixed with PrPc could alter its
properties. When the random coil peptide was incubated with
35S-PrPc at a ratio of 5000:1, it induced protease resistance
(Fig. \A, lanes 1-4). The same peptide in the j8-sheet form did
not produce resistance to proteolysis (lanes 5-7). When Mo
90-145 in either the random coil or /3-sheet form was mixed
with SHaPrPc, it did not induce a change in protease resistance
(lanes 8 and 9).
To localize the region in which PrP peptides interact with
PrPc, we examined shorter peptides. Neither HI containing
residues 109-122 nor a longer version denoted 104H1 com
posed of residues 104-122 could produce protease resistance
in PrPc after mixing (Fig. IB, lanes 2 and 3). In aqueous
buffers, HI rapidly folds into /3-sheets and polymerizes (11)
while 104H1 is random coil (12). SHa 109-141 and SHa
90-145 both gave protease resistance (lanes 4 and 5). The most
efficient formation of protease-resistant radiolabeled PrPc
was seen with the SHa 90-145 (Al 17V) peptide in which V was
substituted for A at position 117 (lane 6). Compared with the
wild-type peptide (lane 4), only 30-40% of the mutant peptide
was needed to produce equivalent amounts of protease-
resistant PrPc. Addition of 2% (wt/vol) Sarkosyldisrupted the
PrPc-peptide complexes and rendered the PrPc sensitive to
protease digestion (data not shown). With SHa 90-145
(A117V), =50% of the 35S-PrPc-peptide complex exhibited
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Fig. 1. Incubation of synthetic PrP peptides with PrPc. 35S-
SHaPrPc and either synthetic peptides or PrPSc were incubated in TN
buffer containing 0.3 M Gdn-HCl for 48 h at 37°C; samples were
digested with proteinase K for 1 h at 37°Cfollowed bySDS/PAGE and
autoradiography. (A) PrPc without proteinase K digestion (lane 1).
SHa 90-145 in a random coil incubated with PrPc with a peptide/PrPc
ratio of 50:1 (lane 2), 500:1 (lane 3), or 5000:1 (lane 4). SHa 90-145
in a j8-sheet with PrPc at 50:1 (lane 5), 500:1 (lane 6), or 5000:1 (lane
7). Mo 90-145 in a random coil with PrPc at 5000:1 (lane 8). Mo
90-145 in a 0-sheet with PrPc at 5000:1 (lane 9). Undenatured
SHaPrPScwith PrPc at 50:1 (lane 10). Lane 1 has 15% of the PrPc in
lanes 2-10. (B) PrPc without proteinase K digestion (lane 1). Peptides
were in a random coil conformation unless otherwise noted and were
incubated with PrPc at a ratio of 5000:1. Lane 2, SHa 109-122 (HI)
was in a /3-sheet conformation. Lane 3, SHa 104-122 (104H1); lane 4,
SHa 90-145; lane 5, SHa 109-141; lane 6, SHa 90-145 (A117V); lane
7, Mo 90-145. Undenatured SHaPrPScwith PrPc 50:1 (lane 8).
protease resistance; with SHa 90-145, only 15-20% was re
sistant.
Properties of PrPc-Peptide Complexes. Since the protease
resistance of the PrPc-peptide complexes resembled that of
PrPSc, we asked if, like PrPSc, the complexeswere insoluble (27,
32, 33). 35S-PrPc was incubated with or without SHa 90-145
(A117V) followed by centrifugation at 100,000 x g. Without
peptide, <10% of the 35S-PrPc was sedimented, whereas
addition of SHa 90-145 (A117V) resulted in =65% of the
radiolabel in the pellet. Fourier transform infrared spectros
copy of the sedimented PrPc-SHa 90-145 complex showed a
substantial increase in /3-sheet content compared to pelleted
PrPc (Fig. 2A). As measured by CD, the supernatant contain
ing primarily unbound SHa 90-145 peptide remained random
coil, as did the peptide incubated alone in TN buffer for 48 h
(data not shown). It is unknown how much of the increase in
/3-sheet content was contributed by PrPc and how much was
contributed by the peptide. Treating PrPc with 50% acetoni-
trile for 48 h at 37°C did not produce protease-resistant PrPc.
When incubated without peptide, PrPc pellets showed many
spherical aggregates up to 20 nm in diameter (Fig. 25). In
contrast, numerous large, filamentous polymers were found in
the pellets of the PrPc-peptide mixture (Fig. 2C).
Anti-PrP mAb Binding to PrPc. Since both anti-PrP 3F4 and
13A5mAbs bind to SHaPrPc within the region spanned by the
SHa 90-145 peptide, we asked if these mAbs could prevent
acquisition of protease resistance. Both mAbs prevented for
mation of protease-resistant PrPc-peptide complexes (Fig. 3A,
lanes 3 and 4).
Spontaneous Formation of Protease-Resistant PrP. We
next asked if PrPc incubated in the absence of PrP peptides
could become protease resistant. Immunopurified PrPc (10
/xg/ml) from CHO cells (Fig. 3B, lanes 1-4) as well as PrPc (1
mg/ml) purified from SHa brain (lanes 5-8) were incubated
for 0 min, 2 min, or 48 h at 37°C in the presence of 0.75 M
11162 Biochemistry: Kaneko et al.
A
1700
I I I I I I I I I I I I I M I
1650 1600
Frequency (cm 1)
Fig. 2. Physical properties of the PrPc-SHa 90-145 complex. (A)
Fourier transform infrared spectra of SHa 90-145 (trace i) and the
complex (trace ii). SHa 90-145 was incubated alone or with SHaPrPc
in TN buffer containing 0.3 M Gdn-HCl for 48 h; samples were
centrifuged at 100,000 x g for 1 h at 20°C and the pellets were
resuspended in TN buffer. (B) Ultrastructure of PrPc negatively
stained with 2% uranyl acetate. (C) PrPc-SHa 90-145 complex
negatively stained with 2% ammonium molybdate. (Bar = 100 nm.)
Gdn-HCl. Before digestion with proteinase K for 1 h at 37°C,
samples were diluted 1:2 with TN buffer (lanes 2-4 and 6-8).
Approximately 1% of the PrPc was found to be protease
resistant after 48 h under these conditions (Fig. 32?)compared
to =50% of the PrPc that was rendered protease resistant with
the SHa 90-145 (A117V) peptide (Fig. 1). PrPc overexpressed
in CHO exhibited a broad size range presumably due to
hyperglycosylation (Fig. 3B, lane 1) in contrast to PrPc from
SHa brain (lane 5). To confirm the identity of the protease-
resistant band, the blot was autoradiographed; after 2 weeks of
exposure, faint but discrete bands of identical size were
detected in lanes containing 35S-PrPc (data not shown). Ad
dition of 0.2% Sarkosyl rendered the protease-resistant PrPc
sensitive to proteolytic digestion.
PrPSc Could Not Be Renatured from Gdn-HCl. Since a small
fraction of PrPc acquired protease resistance when incubated
alone, and a much larger fraction showed resistance when
incubated with synthetic PrP peptides, we revisited the possi
bility that PrPSc mixed with PrPc might render it protease
resistant. Other investigators reported that PrPSc denatured in
Proc. Natl. Acad. Sci. USA 92 (1995)
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Fig. 3. Anti-PrP mAbs prevent PrPc from acquiring protease
resistance; a small fraction of PrPc alone exhibits protease resistance.
(A) 35S-PrPc was incubated for 48 h with either SHa 90-145 peptide
or SHaPrPScin the presence or absence of anti-PrP 3F4 or 13A5 mAb.
PrPc without proteinase K digestion (lanes 1 and 5). SHa 90-145
peptide incubated with PrPc at a molar ratio of 5000:1 (lane 2); the
incubation mixture contained 3F4 (lane 3) or 13A5 mAb (lane 4) in a
mAb/PrPc ratio of 500:1. SHaPrPScwas incubated with PrPc at a ratio
of 50:1 (lane 6); the incubation mixture contained 3F4 (lane 7) or 13A5
mAb (lane 8) in a mAb/PrPc ratio of 500:1. Lanes 1 and 5 have 15%
of the PrPc in lanes 2-4 and 6-8. (B) SHaPrPc was incubated alone
for 0 min, 2 min, or 48 h at 37°C followed by digestion with proteinase
K. Samples were analyzed by SDS/PAGE and Western blotting using
the anti-PrP 3F4 mAb. 35S-SHaPrPc expressed in CHO cells (lanes
1-4) or PrPc purified from SHa brain (lanes 5-8). Lanes 1 and 5 were
not digested and have 15% of the PrPc in lanes 2-4 and 6-8.
3 M Gdn-HCl undergoes renaturation and renders PrPc
resistant to proteolysis within 2 min of mixing (13). Since
numerous attempts to renature prion infectivity from both
Gdn and urea had failed (34), we investigated the effect of 3
M Gdn-HCl on PrPSc. As before, we were unable to demon
strate renaturation of PrPSc that had been denatured in 3 M
Gdn-HCl and then diluted 1:4 to 1:10 before limited protease
digestion and SDS/PAGE (Fig. 4A). Of note, when the
dilution was carried out in the same tube to which the 3 M
Gdn-HCl had been added, we did see protease-resistant PrP
(data not shown). This was never seen when the tubes were
changed, and we surmise that this was due to residual, unde
natured PrPSc bound to the walls of the tube.
When we mixed PrPSc that had been denatured in 3 M
Gdn-HCl and then diluted in buffer to give a final concentra
tion of 0.3-2 M Gdn-HCl with PrPc, no protease-resistant
35S-PrPc could be detected. However, mixing undenatured
prpsc wjtn prpc djjj prociUce protease-resistant 35S-PrPc (Fig.
3A, lane 6). As reported by others (13), a 50-fold excess of
prpsc was required to produce protease-resistant 35S-PrPc,
while a 1:10 excess of PrPSc did not. The presence of 0.3 M
Gdn-HCl in the reaction mixture seems to be essential since its
removal by methanol precipitation before mixing prevented
complex formation. Although =50% of the 35S-PrPc was
recovered in complexes sedimented at 100,000 x gfor 1 h, only
10-15% was protease resistant.
Anti-PrP mAb Prevents Binding of PrPSc to PrPc. The
interaction between PrPc and PrPSc was found to be inhibited
by the anti-PrP 3F4 but not 13A5 mAb (Fig. 14, lanes 7 and
8). This difference between the two mAbs might indicate a
critical role for the PrP residues in the vicinity of the 3F4
epitope, which is at the N terminus of the HI region, or reflect
a difference in the avidity of the two mAbs. PrPc-II truncated
at the N terminus and lacking the 3F4 epitope did not exhibit
Biochemistry: Kaneko et al.
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Fig. 4. Incubation of PrPSc with Gdn-HCl or PrPc. (A) SHaPrPSc
was incubated with 0, 3, or 6 M Gdn-HCl for 1 hr, followed by further
incubation with a 1:4 dilution of Gdn-HCl for 0 min, 2 min, or 48 h at
37°C. Samples were analyzed by SDS/PAGE and Western blotting
using the anti-PrP 3F4 mAb. Lane 1, sample was not digested with
proteinaseK.Lanes2,5, and 8, samples weredigested withproteinase
K at time 0; lanes 3, 6, and 9, samples were digested at 2 min; lanes 4,
7, and 10,samples weredigestedat 48h. Lanes2-4, samplesincubated
without Gdn-HCl; lanes 5-7, samples incubated with 3 M Gdn-HCl;
lanes 8-10, samples incubated with 6 M Gdn-HCl. Equal amounts of
protein were applied to each lane. (B) 35S-SHaPrPc incubated for 48
hwithunlabeledMoPrPSc (lanes1-5) or SHaPrPSc (lanes6-10). Lanes
1 and 6, sampleswere not digestedwith proteinase K; lanes 2 and 7,
samples were digested but in the absence of Sarkosyl. Lanes 3 and 8,
samples wereexposed to 0.2% Sarkosyl and proteinaseKfor 1h; lanes
4 and 9, 1% Sarkosyl; lanes 5 and 10,2% Sarkosyl. Lanes 1 and 6 have
15% of the PrPc in lanes 2-5 and 7-10.
protease resistance after exposure to PrPSc (data not shown),
supporting the notion that the HI region, in which the 3F4
epitope lies, is particularly significant (23, 35).
We estimate that 15-20% of PrPc mixed with PrPSc acquired
protease resistance after 48 h in contrast to mixing with the
SHa 90-145 (A117V) peptide where «50% PrPc demon
strated protease resistance.After incubationwith SHa 90-145
for 1 h, «35% of the 35S-PrPc that exhibited protease resis
tance at 48 h was present; by 24 h, ^75% of the PrPc was
protease resistant. Although it has been reported that pro-
tease-resistant 35S-PrPc was generated within 2 min after
mixing with a 50-fold excess of unlabeled PrPSc, we were
unable to reproduce this finding (13).
Species Specificity of PrPSc Binding to PrPc. When we
mixed MoPrPSc with SHaPrPc, relatively little protease-
resistant PrPc wasformed (Fig. AB, lanes 1 and 2) and addition
of Sarkosyl rendered the complex sensitive to proteolysis
(lanes 3-5). In contrast, the 35S-PrPc-SHaPrPSc complex was
resistant to proteolysis (lanes 6-10), even when exposed to up
to 2% Sarkosyl for 48 h before digestion. These results are
consistent with the finding that SHa 90-145 mixed with
SHaPrPc produced protease-resistant protein, whereas Mo
90-145 mixed with SHaPrPc did not (Fig. 1).
Attempts to Disrupt PrPc-PrPSc Complexes. Although ad
dition of Sarkosyl to the PrPc-peptide complexes or PrPc
alone abolished protease resistance, this was not the case for
the PrPc-PrPSc complexes. Additional attempts to disrupt the
prpc_prpsc complexes under conditions likely to preserve
Proc. Natl. Acad. Sci. USA 92 (1995) 11163
scrapie prion infectivity utilized detergents such as Nonidet
P-40, Tween 20, Zwittergent 3-12, and sodium deoxycholate
alone or in combination with phospholipids to form detergent-
lipid-protein complexes (36). We also investigated the possi
bilityof disruptingthese complexes by usingthe anti-PrP 3F4
mAb and synthetic peptides containing residues 109-122 or
90-145. Although the mAb and peptides were added to the
complexes in molar ratios of 1000:1, they were unable to
dissociate the 35S-PrPc from PrPSc. Addition of a 10-fold excess
of unlabeled PrPc from CHO cells also failed to displace the
35S-PrPc from the complex. These results prevented us from
determiningwhether PrPc had acquired protease resistanceor
displayed this property because it was bound to PrPSc.
PrPc Purified from SHa Brain. Attempts to render PrPc
purified from SHa brain protease resistant by mixing with
prpsc were unsuccessful. Why 35S-SHaPrPc immunoaffinity
purified from CHO cells did bind to SHaPrPSc and 125I-
SHaPrPc purified from brain did not is unclear. Besides
iodination, other possible factors to explain this discrepancy
include residual anti-PrP mAbs in immunoaffinity-purified
preparations of PrPc from the CHO cells, an unidentified
factor such as protein X (37) in CHO cell lysates that purifies
with PrPc, or the conformation of PrPc purified from brain
differs significantly from that of CHOcell-derived PrPc.The
presence or absence of the diacylglycerol moiety of the gly-
cosylphosphatidylinositol anchor does not seem to be a sig
nificant factor since 35S-PrPctreated with phosphatidylinositol
phospholipase C yielded the same degree of protease resis
tance after mixing with PrPSc as controls not treated with
phosphatidylinositol phospholipase Cj
DISCUSSION
Investigations with chimeric transgenes showed that PrPcand
prpsc are iikeiy to interact within a central domain delimited
by codons 96 and 169 (37-40). The investigations reported
here using synthetic peptides binding to PrPc provide physical
data confirming the conclusions drawn from the results of the
transgenetic studies. Furthermore, such studies should permit
a detailed assessment of the size of the interactive region as
well as defining which residues are critical. Transgenetic
studies have also implicated another protein that participates
in the formation of PrPSc by binding to PrPc. This protein,
provisionally designated protein X, mayfunction as a molec
ular chaperone in mediating the transformation of PrPc into
PrPSc (37).
Although other investigators have reported the in vitro
formation of PrPSc by mixing a 50-fold excess of PrPSc with
35S-PrPc, their conclusions assume that protease-resistant
PrPc is equivalent to PrPSc (13). Interestingly, the binding of
PrPc to PrPScwas found to be dependent on the same residues
(41) that render transgenic MH2M mice susceptible to SHa
prions (39) and it seems to be strain dependent (42).Although
we were able to confirm the binding of PrPc to PrPSc in the
presence of a large excess of PrPSc (Fig. 3A and AB), we were
unable to reproduce the renaturation of PrPSc from Gdn-HCl
as judged by a restoration of protease resistance (Fig. AA).
Attempts to separate 35S-PrPc from PrPSc under conditions
where scrapie infectivity is preserved were unsuccessfulwith a
variety of detergents, anti-PrP mAbs, detergent-lipid-protein
complexes, and synthetic peptides. Until such conditions are
identified, we cannot determine whether PrPc has been con
verted into PrPSc or is only tightly bound. The experiments
presented herewithPrPpeptides thatbindto PrPcandrender
it protease resistant argue that the latter possibility is more
likely to be correctsince Sarkosyl disrupted the PrPc-peptide
complex and made PrPc sensitive to protease.
Some investigators continue to contend that PrP amyloids
participate in PrPSc formation (13, 41-45) despite much evi
dence to the contrary. Although PrP amyloid plaques were
""*•"»
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found in transgenic SHaPrP mice inoculated with SHa prions,
none were detected in the mice inoculated with Mo prions (3).
Thus, amyloid deposition in plaque formation is not obligatory
for prion propagation. Ultrastructural studies demonstrated
that purified PrPSc molecules exist as amorphous aggregates,
which, when partially digested with proteinase K in the pres
ence of detergent, form PrP 27-30 that polymerizes into
rod-shaped particles with the properties of amyloid (5, 33).
The SHa 90-145 peptide adopts an a-helical structure in
hydrophobic environments created by detergents or lipids
while it displays a random coil in H20 (14). Although 2-3
weeks was required for SHa 90-145 in the presence of 150 mM
NaCl to acquire j3-sheet conformation and resistance to pro
teolysis, it displayed these features after 48 h upon mixing with
PrPc. While these physical properties of SHa 90-145 resemble
those of PrPSc, this peptide injected intracerebrally into ro
dents has not produced central nervous system dysfunction to
date.
Our investigations offer an additional approach to the study
of prions. Synthetic PrP peptides can be used to map regions
where PrP molecules interact with each other and to define the
degree of homology that facilitates binding. It is likely that this
knowledge can be translated to direct the construction of PrP
transgenes with predetermined specificities. Since the PrP
peptides used in our studies have not exhibited prion infec
tivity, it will be possible to determine whether the PrPc-
peptidecomplexes that mimic manyof the featuresof PrPSc are
capable of transmitting prion disease in inoculated animals.
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